The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1704
June 10, 2024
View Complete Issue         Table of Contents 2019 
Beqvez — Another Gene Therapy for Hemophilia B
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Beqvez — Another Gene Therapy for Hemophilia B
June 10, 2024 (Issue: 1704)
Fidanacogene elaparvovec-dzkt (Beqvez – Pfizer), an adeno-associated virus (AAV) vector-based gene therapy, has been approved by the FDA for treatment of adults with moderate to severe hemophilia B who do not have neutralizing antibodies to AAV...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Beqvez — Another Gene Therapy for Hemophilia B
Article code: 1704d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.